interferon

Overview

Interferons are a family of cytokines with central roles in innate and adaptive immunity, especially in antiviral defense, immune regulation, and tumor surveillance. They are commonly grouped into type I interferons, type II interferon, and type III interferons, with interferon-γ (IFN-γ) being the best-known type II member. Interferon signaling induces broad transcriptional programs that can enhance antigen presentation, activate cytotoxic lymphocytes and macrophages, and shape inflammatory responses through pathways such as JAK-STAT.

Clinically, interferons have long been studied as therapeutic agents and as biomarkers of immune activation or dysregulation. Their effects are context dependent: they can support host defense against viruses and intracellular pathogens, but excessive, prolonged, or misdirected interferon activity can also contribute to tissue inflammation, immune exhaustion, and pathological remodeling in diseases such as COVID-19, cancer, autoimmune disorders, and hemophagocytic syndromes. In recent biomedical research, interferon pathways are frequently examined alongside checkpoint inhibitor therapy, PD-1/PD-L1 blockade, STING1 activation, cGAS-STING pathway signaling, and cytokine-based immunomodulation.

Recent Publications Summary

Recent publications have extensively investigated interferon, particularly interferon-γ (IFN-γ), as a central regulator of antitumor immunity across multiple cancer types. Type II interferon was identified as essential for dendritic cell maturation and tertiary lymphoid structure development in lung cancer, and for priming CD4+ Th1 responses in poorly immunogenic pancreatic cancer treated with STING agonist and checkpoint inhibitors 42462020Jul42102812May. IFN-γ production characterized protective CD4+ and CD8+ T cell responses following SARS-CoV-2 vaccination, with vaccinated mice displaying strong Th1-biased cellular immunity and multifunctional T cell responses 42423335Jul. In lung adenocarcinoma, tumors with high interferon and antigen presentation gene expression predicted superior responses to immunotherapy 42013848Apr. Type II interferon also controlled neutrophil function during cancer immunotherapy; IFN-γ produced by cytotoxic lymphocytes induced PD-L1 expression on neutrophils in a cell-intrinsic manner, and genetic deletion of interferon-γ receptor on neutrophils reversed their immunosuppressive phenotype 42296966Jun.

Interferon signaling dysregulation, however, contributed to treatment resistance and transplant rejection. JAK-STAT-interferon pathway dynamics distinguished permissive from rejecting liver allografts, with elevated interferon-stimulated gene expression and JAK-STAT activation evident in recipients with subclinical rejection at 12 months 42555758Aug. In pancreatic cancer, interferon-γ-inducible MHC-I expression was selectively lost on metastatic variants during checkpoint blockade, whereas restoring MHC-I expression with anti-CTLA-4 prolonged survival 42361199Jun. tumor cell-derived interferon paradoxically promoted PARP inhibitor resistance in ovarian cancer by inducing osteopontin expression in tumor-associated macrophages via STAT signaling, creating immunosuppressive niches; high baseline osteopontin expression predicted lower response rates and shorter progression-free survival 41734034Feb.

Beyond malignancy, interferon-γ was evaluated as a therapeutic target and adjunctive immunotherapy. Emapalumab, a monoclonal antibody against interferon-γ, combined with conventional therapy or ruxolitinib showed promise in hemophagocytic lymphohistiocytosis, a cytokine-driven hyperinflammatory syndrome 42397658Jul. Interferon-γ administered with anti-PD-1 antibodies in patients with life-threatening invasive mold infections resulted in survival in six of eight treated patients with generally tolerable side effects 42171361May. In severe pediatric acute respiratory distress syndrome, dysregulated interferon signaling characterized disease pathology, with interferon-driven cytotoxic CD8+ T cell profiles, elevated interferon-stimulated gene expression in pulmonary immune cells, and suppressed interleukin-1 signaling correlating with disease severity 42140972May.

What Changes, What Holds

1. Interferon-γ simultaneously drives antigen presentation and neutrophil-mediated immunosuppression
REINFORCES IFN-γ confirmed to enhance antigen presentation and activate Th1 responses across multiple cancer types and vaccination models 42462020Jul42013848Apr42423335Jul. However, IFN-γ from cytotoxic lymphocytes also induces PD-L1 on neutrophils, creating immunosuppression reversible by blocking IFN-γR 42296966Jun, exemplifying the baseline's established principle that interferon effects are context-dependent within the same immune microenvironment.

2. tumor-derived interferon programs macrophage-mediated PARP inhibitor resistance
NEW DIRECTION ovarian cancer cells deploy interferon to induce osteopontin in tumor-associated macrophages, promoting PARP inhibitor resistance 41734034Feb—a therapy-resistance mechanism not addressed by the baseline. Elevated JAK-STAT-interferon signaling also characterizes rejecting liver transplants 42555758Aug, showing interferon dysregulation in a disease context outside the baseline's scope. Metastatic pancreatic tumors selectively lose IFN-γ-inducible MHC-I expression during checkpoint blockade 42361199Jun.

3. Interferon-γ combined with checkpoint inhibitors rescues life-threatening invasive fungal infections
NEW DIRECTION IFN-γ administered with anti-PD-1 achieved survival in six of eight patients with life-threatening invasive mold infections 42171361May—demonstrating a novel therapeutic combination not previously tested in infectious disease. Dysregulated interferon also characterized severe pediatric ARDS, with elevated interferon-stimulated genes correlating with disease severity 42140972May, showing respiratory disease as a new context for interferon pathology, while emapalumab (anti-IFN-γ) in hemophagocytic syndrome reinforces the baseline's principle of blocking interferon in hyperinflammatory states 42397658Jul.

Overview update candidates: tumor-derived interferon as a mechanism of drug resistance in cancer; interferon dysregulation in pediatric ARDS as a driver of disease pathology; interferon-γ combined with checkpoint inhibitors in invasive fungal infections.